# A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom

> **NCT05782764** · PHASE4 · UNKNOWN · sponsor: **Xuzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Lung Squamous Cell Carcinoma

## Interventions

- **DRUG:** To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).

## Key facts

- **NCT ID:** NCT05782764
- **Lead sponsor:** Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-05-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05782764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05782764, "A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05782764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*